Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Announces 1-for-30 Reverse Stock Split

NEW YORK – Cancer Genetics on Thursday announced a 1-for-30 reverse stock split of its outstanding common stock, effective at the start of trading on Friday.

In Thursday morning trading on the Nasdaq, the company's shares were down more than 10 percent at $.12.

The Rutherford, New Jersey-based provider of preclinical test systems said that the reverse stock split is intended to increase its stock price to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq.

The reverse stock split will reduce the number of shares of common stock issued and outstanding from about 63 million to about 2.1 million, Cancer Genetics said.

In April, Cancer Genetics announced that its fourth quarter revenues fell 9 percent year over year.

The firm had announced in January that it was looking to raise $3 million in a stock offering that it subsequently closed.

A month earlier, the company said it had cancelled a previously announced planned merger with Jerusalem-based NovellusDx.


The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.